BSH/ISH 2016 | How to manage infections in CLL patients on idelalisib
Andrew Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, New York, NY discusses the management of infections when treating chronic lymphocytic leukemia (CLL) patients with idelalisib. For opportunistic infections, it is important to provide prophylaxis when it comes to pneumocystis. Dr Zelenetz also discusses enhanced neutropenia and the use of dapsone. For cytomegalovirus (CMV), the key is monitoring.
Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland.
Get great new content delivered to your inboxSign up